This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Piper Jaffray Appoints Dr. Charles Duncan To Expand Biotechnology Research Platform

Stocks in this article: PJC

Piper Jaffray (NYSE: PJC) is pleased to announce the addition of Dr. Charles Duncan as managing director and senior research analyst in its biotechnology research platform. He will be based in the firm’s New York office, focused specifically on small- and mid-cap emerging growth biotechnology companies.

Duncan brings more than 17 years of sell-side experience, most recently serving as an analyst at JMP Securities since 2002, and previously at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis.

"Piper Jaffray is highly committed to further advancing its market leading position in specialty areas of healthcare, including biotechnology. Charles adds experience to an already well-established platform, now with a total of four senior analysts and a significant coverage footprint across specialty pharmaceuticals and biotechnology sectors,” commented Jeff Klinefelter, global head of equities for Piper Jaffray. “The firm will continue to focus efforts on providing growth companies with strategic alternatives for funding, while offering investors opportunities to participate in early-stage growth in exciting areas of drug discovery."

Duncan began his career as a manager of clinical development at Global Drug Development, Inc., a pharmaceutical development consulting firm where he also launched InfusionVision Medical, a venture-backed start-up medical device company. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.

Piper Jaffray has a total of 30 senior research analysts located in Minneapolis, New York, San Francisco and Chicago. The firm provides coverage on 565 companies globally in key sectors: business and financial services; clean technology and renewables; consumer; healthcare; industrials; and technology, media and telecommunications.

About Piper JaffrayPiper Jaffray is a leading investment bank and asset management firm serving clients in the U.S. and internationally. Proven advisory teams combine deep industry, product and sector expertise with ready access to capital. Founded in 1895, the firm is headquartered in Minneapolis and has offices across the United States and in London and Zurich. www.piperjaffray.com

Since 1895. Member FINRA, NYSE and SIPC.© 2012 Piper Jaffray & Co.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs